Comparison of Circulating Tumour Cells and Circulating Cell-Free Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy

Abstract Quantification of Epstein-Barr virus (EBV) cell-free DNA (cfDNA) is commonly used in clinical settings as a circulating biomarker in nasopharyngeal carcinoma (NPC), but there has been no comparison with circulating tumour cells (CTCs). Our study aims to compare the performance of CTC enumer...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jess Honganh Vo, Wen Long Nei, Min Hu, Wai Min Phyo, Fuqiang Wang, Kam Weng Fong, Terence Tan, Yoke Lim Soong, Shie Lee Cheah, Kiattisa Sommat, Huiyu Low, Belinda Ling, Johnson Ng, Wan Loo Tan, Kian Sing Chan, Lynette Oon, Jackie Y. Ying, Min-Han Tan
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2016
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/dbe3a09afaab447aa9b5d756ba3c8eef
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dbe3a09afaab447aa9b5d756ba3c8eef
record_format	dspace
spelling	oai:doaj.org-article:dbe3a09afaab447aa9b5d756ba3c8eef2021-12-02T15:05:52ZComparison of Circulating Tumour Cells and Circulating Cell-Free Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy10.1038/s41598-016-0006-32045-2322https://doaj.org/article/dbe3a09afaab447aa9b5d756ba3c8eef2016-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-016-0006-3https://doaj.org/toc/2045-2322Abstract Quantification of Epstein-Barr virus (EBV) cell-free DNA (cfDNA) is commonly used in clinical settings as a circulating biomarker in nasopharyngeal carcinoma (NPC), but there has been no comparison with circulating tumour cells (CTCs). Our study aims to compare the performance of CTC enumeration against EBV cfDNA quantitation through digital PCR (dPCR) and quantitative PCR. 74 plasma samples from 46 NPC patients at baseline and one month after radiotherapy with or without concurrent chemotherapy were analysed. CTCs were captured by microsieve technology and enumerated, while three different methods of EBV cfDNA quantification were applied, including an in-house qPCR assay for BamHI-W fragment, a CE-IVD qPCR assay (Sentosa ®) and a dPCR (Clarity™) assay for Epstein-Barr nuclear antigen 1 (EBNA1). EBV cfDNA quantitation by all workflows showed stronger correlation with clinical stage, radiological response and overall survival in comparison with CTC enumeration. The highest detection rate of EBV cfDNA in pre-treatment samples was seen with the BamHI-W qPCR assay (89%), followed by EBNA1-dPCR (85%) and EBNA1-qPCR (67%) assays. Overall, we show that EBV cfDNA outperforms CTC enumeration in correlation with clinical outcomes of NPC patients undergoing treatment. Techniques such as dPCR and target selection of BamHI-W may improve sensitivity for EBV cfDNA detection.Jess Honganh VoWen Long NeiMin HuWai Min PhyoFuqiang WangKam Weng FongTerence TanYoke Lim SoongShie Lee CheahKiattisa SommatHuiyu LowBelinda LingJohnson NgWan Loo TanKian Sing ChanLynette OonJackie Y. YingMin-Han TanNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 6, Iss 1, Pp 1-9 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jess Honganh Vo Wen Long Nei Min Hu Wai Min Phyo Fuqiang Wang Kam Weng Fong Terence Tan Yoke Lim Soong Shie Lee Cheah Kiattisa Sommat Huiyu Low Belinda Ling Johnson Ng Wan Loo Tan Kian Sing Chan Lynette Oon Jackie Y. Ying Min-Han Tan Comparison of Circulating Tumour Cells and Circulating Cell-Free Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy
description	Abstract Quantification of Epstein-Barr virus (EBV) cell-free DNA (cfDNA) is commonly used in clinical settings as a circulating biomarker in nasopharyngeal carcinoma (NPC), but there has been no comparison with circulating tumour cells (CTCs). Our study aims to compare the performance of CTC enumeration against EBV cfDNA quantitation through digital PCR (dPCR) and quantitative PCR. 74 plasma samples from 46 NPC patients at baseline and one month after radiotherapy with or without concurrent chemotherapy were analysed. CTCs were captured by microsieve technology and enumerated, while three different methods of EBV cfDNA quantification were applied, including an in-house qPCR assay for BamHI-W fragment, a CE-IVD qPCR assay (Sentosa ®) and a dPCR (Clarity™) assay for Epstein-Barr nuclear antigen 1 (EBNA1). EBV cfDNA quantitation by all workflows showed stronger correlation with clinical stage, radiological response and overall survival in comparison with CTC enumeration. The highest detection rate of EBV cfDNA in pre-treatment samples was seen with the BamHI-W qPCR assay (89%), followed by EBNA1-dPCR (85%) and EBNA1-qPCR (67%) assays. Overall, we show that EBV cfDNA outperforms CTC enumeration in correlation with clinical outcomes of NPC patients undergoing treatment. Techniques such as dPCR and target selection of BamHI-W may improve sensitivity for EBV cfDNA detection.
format	article
author	Jess Honganh Vo Wen Long Nei Min Hu Wai Min Phyo Fuqiang Wang Kam Weng Fong Terence Tan Yoke Lim Soong Shie Lee Cheah Kiattisa Sommat Huiyu Low Belinda Ling Johnson Ng Wan Loo Tan Kian Sing Chan Lynette Oon Jackie Y. Ying Min-Han Tan
author_facet	Jess Honganh Vo Wen Long Nei Min Hu Wai Min Phyo Fuqiang Wang Kam Weng Fong Terence Tan Yoke Lim Soong Shie Lee Cheah Kiattisa Sommat Huiyu Low Belinda Ling Johnson Ng Wan Loo Tan Kian Sing Chan Lynette Oon Jackie Y. Ying Min-Han Tan
author_sort	Jess Honganh Vo
title	Comparison of Circulating Tumour Cells and Circulating Cell-Free Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy
title_short	Comparison of Circulating Tumour Cells and Circulating Cell-Free Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy
title_full	Comparison of Circulating Tumour Cells and Circulating Cell-Free Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy
title_fullStr	Comparison of Circulating Tumour Cells and Circulating Cell-Free Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy
title_full_unstemmed	Comparison of Circulating Tumour Cells and Circulating Cell-Free Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy
title_sort	comparison of circulating tumour cells and circulating cell-free epstein-barr virus dna in patients with nasopharyngeal carcinoma undergoing radiotherapy
publisher	Nature Portfolio
publishDate	2016
url	https://doaj.org/article/dbe3a09afaab447aa9b5d756ba3c8eef
work_keys_str_mv	AT jesshonganhvo comparisonofcirculatingtumourcellsandcirculatingcellfreeepsteinbarrvirusdnainpatientswithnasopharyngealcarcinomaundergoingradiotherapy AT wenlongnei comparisonofcirculatingtumourcellsandcirculatingcellfreeepsteinbarrvirusdnainpatientswithnasopharyngealcarcinomaundergoingradiotherapy AT minhu comparisonofcirculatingtumourcellsandcirculatingcellfreeepsteinbarrvirusdnainpatientswithnasopharyngealcarcinomaundergoingradiotherapy AT waiminphyo comparisonofcirculatingtumourcellsandcirculatingcellfreeepsteinbarrvirusdnainpatientswithnasopharyngealcarcinomaundergoingradiotherapy AT fuqiangwang comparisonofcirculatingtumourcellsandcirculatingcellfreeepsteinbarrvirusdnainpatientswithnasopharyngealcarcinomaundergoingradiotherapy AT kamwengfong comparisonofcirculatingtumourcellsandcirculatingcellfreeepsteinbarrvirusdnainpatientswithnasopharyngealcarcinomaundergoingradiotherapy AT terencetan comparisonofcirculatingtumourcellsandcirculatingcellfreeepsteinbarrvirusdnainpatientswithnasopharyngealcarcinomaundergoingradiotherapy AT yokelimsoong comparisonofcirculatingtumourcellsandcirculatingcellfreeepsteinbarrvirusdnainpatientswithnasopharyngealcarcinomaundergoingradiotherapy AT shieleecheah comparisonofcirculatingtumourcellsandcirculatingcellfreeepsteinbarrvirusdnainpatientswithnasopharyngealcarcinomaundergoingradiotherapy AT kiattisasommat comparisonofcirculatingtumourcellsandcirculatingcellfreeepsteinbarrvirusdnainpatientswithnasopharyngealcarcinomaundergoingradiotherapy AT huiyulow comparisonofcirculatingtumourcellsandcirculatingcellfreeepsteinbarrvirusdnainpatientswithnasopharyngealcarcinomaundergoingradiotherapy AT belindaling comparisonofcirculatingtumourcellsandcirculatingcellfreeepsteinbarrvirusdnainpatientswithnasopharyngealcarcinomaundergoingradiotherapy AT johnsonng comparisonofcirculatingtumourcellsandcirculatingcellfreeepsteinbarrvirusdnainpatientswithnasopharyngealcarcinomaundergoingradiotherapy AT wanlootan comparisonofcirculatingtumourcellsandcirculatingcellfreeepsteinbarrvirusdnainpatientswithnasopharyngealcarcinomaundergoingradiotherapy AT kiansingchan comparisonofcirculatingtumourcellsandcirculatingcellfreeepsteinbarrvirusdnainpatientswithnasopharyngealcarcinomaundergoingradiotherapy AT lynetteoon comparisonofcirculatingtumourcellsandcirculatingcellfreeepsteinbarrvirusdnainpatientswithnasopharyngealcarcinomaundergoingradiotherapy AT jackieyying comparisonofcirculatingtumourcellsandcirculatingcellfreeepsteinbarrvirusdnainpatientswithnasopharyngealcarcinomaundergoingradiotherapy AT minhantan comparisonofcirculatingtumourcellsandcirculatingcellfreeepsteinbarrvirusdnainpatientswithnasopharyngealcarcinomaundergoingradiotherapy
_version_	1718388675163717632

Comparison of Circulating Tumour Cells and Circulating Cell-Free Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy

Ejemplares similares